急性髓系白血病基因组学
急性髓系白血病(AML)是生物学复杂、分子和临床异质性疾病,标准治疗三十年未显著改变。本文综述新预后标志物进展,包括可靶向突变,可能指导分子靶向治疗开发与应用。
要点
- 表观遗传修饰基因(DNMT3A、ASXL1、TET2、IDH1、IDH2)突变常早期获得并存在于 founding clone。
- NPM1 或信号分子(如 FLT3、RAS 基因家族)突变通常为白血病发生后期的次要事件。
- 新预后标志物(含可靶向突变)可能指导分子靶向治疗的开发与应用。
核心结论
- AML 是生物学复杂、分子和临床异质性疾病,标准治疗在过去三十年中未显著改变。
研究设计与样本
- 综述,旨在概述新预后标志物进展,包括可靶向突变。
主要发现
- 表观遗传修饰基因(如 DNMT3A、ASXL1、TET2、IDH1、IDH2)突变常早期获得并存在于 founding clone。
- NPM1 或信号分子(如 FLT3、RAS 基因家族)突变通常为白血病发生后期出现的次要事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) is a biologically complex, molecularly and clinically heterogeneous disease. Despite major advances in understanding the genetic landscape of AML and its impact on the pathophysiology and biology of the disease, standard treatment options have not significantly changed during the past three decades. AML is characterized by multiple somatically acquired mutations that affect genes of different functional categories. Mutations in genes encoding epigenetic modifiers, such as DNMT3A, ASXL1, TET2, IDH1, and IDH2, are commonly acquired early and are present in the founding clone. By contrast, mutations involving NPM1 or signalling molecules (e.g., FLT3, RAS gene family) are typically secondary events that occur later during leukaemogenesis. This review aims to provide an overview of advances in new prognostic markers, including targetable mutations that will probably guide the development and use of novel molecularly targeted therapies.
引用
- Medinger M, Passweg JR. Acute myeloid leukaemia genomics. Br J Haematol. 2017. PMID: 28653397. doi:10.1111/bjh.14823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。